RxDoctor Payments Data

Shakira Shanker, MD

Neurology · Commack, NYNPI 1144631987

Payments from drug & device makers

$78,876in general payments, 2019–2025

Across 879 payments — averaging $89.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$48K
  • Axsome Therapeutics, Inc.$16K
  • Argenx US, Inc.$2K
  • Harmony Biosciences LLC$1K
  • Lundbeck LLC$887
  • Takeda Pharmaceuticals U.S.A., Inc.$885
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$1,1251%
  • Speaking & faculty fees$56,74472%
  • Travel & lodging$1,1651%
  • Food & beverage$19,70225%
  • Education$1400%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)269$48,040
Axsome Therapeutics, Inc.24$16,005
Argenx US, Inc.33$2,454
Harmony Biosciences LLC53$1,133
Lundbeck LLC60$887
Takeda Pharmaceuticals U.S.A., Inc.27$885
AstraZeneca(2 entities)29$855
Pfizer42$784
Amgen(2 entities)30$672
Neurocrine Biosciences, Inc.20$568
Amneal Pharmaceuticals LLC26$564
UCB, Inc.18$418
Scilex Pharmaceuticals Inc.15$327
CSL Behring12$312
Catalyst Pharmaceuticals, Inc.10$281
Sanofi11$275
Merz Pharmaceuticals, LLC11$268
Teva Pharmaceuticals USA, Inc.2$255
Grifols USA, LLC10$237
Lilly USA, LLC11$227
Biohaven Pharmaceutical Holding Company Ltd.11$226
Biogen12$210
SK Life Science, Inc.7$188
Ipsen Biopharmaceuticals, Inc7$187
Biohaven Pharmaceuticals, Inc.7$185
Novartis11$175
Supernus Pharmaceuticals, Inc.8$159
Boston Scientific2$154
Currax Pharmaceuticals LLC8$133
Medtronic4$127
Upsher-smith Laboratories LLC6$123
Almatica Pharma LLC7$116
Eisai Inc.4$81
Protega Pharmaceutials Inc5$81
Tanabe Pharma America, Inc.4$77
Merz North America, Inc.3$74
Avanir Pharmaceuticals, Inc.3$70
Vanda Pharmaceuticals Inc.4$70
ZOLL Respicardia, Inc.1$70
Impel Pharmaceuticals Inc.4$69
Octapharma USA, Inc.3$66
Averitas Pharma Inc.4$61
Inspire Medical Systems, Inc.2$58
Merck4$56
Kyowa Kirin, Inc.2$54
MDD US Operations, LLC4$51
GRT US Holding, Inc.3$46
Arbor Pharmaceuticals, Inc.3$46
Collegium Pharmaceutical, Inc.3$44
Adamas Pharmaceuticals, Inc.2$40
Tonix Medicines, Inc.2$38
Acadia Pharmaceuticals Inc2$36
EMD Serono, Inc.1$28
Baudax Bio Inc.1$25
Forte Bio-pharma LLC1$24
Amylyx Pharmaceuticals, Inc.1$24
Alnylam Pharmaceuticals Inc.1$21
Sunovion Pharmaceuticals Inc.2$21
Impel Pharmaceuticals LLC1$20
Neurelis, Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$78,876 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$307,439
Medicare patients
621
Services billed
10,743

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BotoxOnabotulinumtoxina50$64,784
Nurtec OdtRimegepant Sulfate32$51,974
UbrelvyUbrogepant27$30,133
QuliptaAtogepant20$26,302
VyeptiEptinezumab-Jjmr11$23,293
Aimovig AutoinjectorErenumab-Aooe21$15,133
Memantine Hcl ErMemantine Hcl39$3,037
Sumatriptan Succinate47$1,152
Gabapentin129$917
Pyridostigmine Bromide24$666
Memantine Hcl74$661
Donepezil Hcl111$653
Propranolol Hcl58$637
Carbidopa-LevodopaCarbidopa/Levodopa50$630
Pregabalin31$538

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$48,040$121,21897 claims
PfizerNurtec Odt$784$51,97432 claims
Lundbeck LLCVyepti$887$23,29311 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$564$66624 claims
Upsher-smith Laboratories LLCTopiramate$123$17126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Commack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →